"90%"@en . "Mianserina"@en . . . . . . "approved"@en . " "@en . "# Koyama E, Chiba K, Tani M, Ishizaki T: Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther. 1996 Jul;278(1):21-30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8764331 # de Boer TH, Nefkens F, van Helvoirt A, van Delft AM: Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther. 1996 May;277(2):852-60. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8627567 # Kelder J, Funke C, De Boer T, Delbressine L, Leysen D, Nickolson V: A comparison of the physicochemical and biological properties of mirtazapine and mianserin. J Pharm Pharmacol. 1997 Apr;49(4):403-11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9232538"@en . "Mianserin's mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors."@en . . " "@en . "Mianserinum"@en . . . "Humans and other mammals"@en . . . . . . "Mianseryna"@en . . . . . "For the treatment of depression."@en . . "Oral rat LD₅₀: 780mg/kg"@en . . . . . "Mianserine"@en . . . . . . . . "24219-97-4"@en . . . "Absorbed following oral administration."@en . . . "1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,F)pyrazino(1,2-a)azepine"@en . . "A tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favor of Mirtazapine."@en . . . . . "10-17 hours"@en . "Mianserin"@en . .